Skip to main content
Clinical Trials/NCT04744181
NCT04744181
Completed
Not Applicable

Patient Blood Management In CARdiac sUrgical patientS: the ICARUS Study

Fondazione Policlinico Universitario Agostino Gemelli IRCCS1 site in 1 country479 target enrollmentJanuary 18, 2021

Overview

Phase
Not Applicable
Intervention
Ferric carboxymaltose
Conditions
Anemia
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Enrollment
479
Locations
1
Primary Endpoint
Percentage of patients receiving RBC transfusion within post-operative day 7
Status
Completed
Last Updated
8 months ago

Overview

Brief Summary

Nowadays up to 40% of patients undergoing cardiac surgery receives at least 1 unit of red blood cell transfusion during surgery or during the first week after surgery. Moreover up to 40% of these patients shows an absolute or relative iron deficiency, with or without anaemia.

The objective of this study is to assess whether to implement an adequate correction of iron according to current "patients blood management" recommendations might reduce RBC transfusion requirements in patients undergoing heart surgery.

Data obtained in patients included in the study will be compared to those of a case-control population selected from patients consecutively treated at the same department in the previous 2 years.

Detailed Description

Anemia is defined by the World Health Organization (WHO) as a value of hemoglobin (Hb) \< 130 g/L in men and \< 120 g/L in women. Anemia in surgical patients is a common and serious problem, in fact up to 40% of patients presenting for major surgery are anemic. Patients with pre-operative anemia have significantly higher rates of morbidity and mortality and are likely to receive red blood cell (RBC) transfusions. In turn, RBC are independently associated with worse outcome. Preoperative anemia mainly results from inadequate erythropoiesis owing to iron deficiency. Iron deficiency anemia (IDA) has a complex origin, including either absolute or functional iron deficiency (or iron sequestration). In absolute iron deficiency, iron stores are severely decreased, resulting in anaemia (IDA). Conversely, functional iron deficiency refers to insufficient iron mobilization despite normal or elevated iron stores (iron deficient erythropoiesis, IDE).The most rapid and simple method to correct anaemia is RBC transfusion. More than 30% of cardiac patients receives blood products in the peri-operative phase. However, blood transfusion itself is not without risk: in the setting of cardiac patients, even a single unit of blood transfused is reported to be associated to increased morbidity and mortality. Specifically, blood transfusions in cardiac surgery are associated with infections, ischemic postoperative morbidity, hospital stay, increased early and late mortality, and greater hospital costs. Preoperative correction of iron deficiency, with or without anaemia, is an integral part of the concept of the Patient Blood Management (PBM). Iron supplementation would increase the availability of iron stores and would trigger the process of erythropoiesis; the consequent relative lack of vitamin B12 and folic acid makes fundamental to restore also these 2 vitamins. The objective of this study is to assess whether to implement an adequate correction of IDA and IDE according to current PBM recommendations might reduce RBC transfusion requirements in patients undergoing heart surgery. Data obtained in patients included in the study will be compared to those of a case-control population selected from patients consecutively treated at the same department in the previous 2 years.

Registry
clinicaltrials.gov
Start Date
January 18, 2021
End Date
January 31, 2022
Last Updated
8 months ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

CORSI FILIPPO

Principal Investigator

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Eligibility Criteria

Inclusion Criteria

  • all adult patients candidate to planned heart surgery

Exclusion Criteria

  • Pregnancy
  • Know allergy to iron, or B vitamin, or folic acid
  • Hyperferritinemia (ferritin blood value \> 300 ng/ml).
  • patient's refusal

Arms & Interventions

cases

patients who fulfill the inclusion criteria

Intervention: Ferric carboxymaltose

cases

patients who fulfill the inclusion criteria

Intervention: B vitamin

cases

patients who fulfill the inclusion criteria

Intervention: Folic acid

Outcomes

Primary Outcomes

Percentage of patients receiving RBC transfusion within post-operative day 7

Time Frame: within post operative day 7

Percentage of patients receiving RBC transfusion within post-operative day 7

Secondary Outcomes

  • length of stay in ICU(through study completion, an average of 1 year)
  • number of allogeneic blood products administered(within the first 7 days post operative)
  • acute kidney injury(within the first 7 days post operative)
  • serious adverse events(within the first 12 hours after administration)
  • mortality(within the first 7 days after surgery)
  • Hb values at last postoperative control within 7 days from surgery(within post operative day 7)
  • duration of mechanical ventilation(within the first 7 days post operative)
  • infections requiring antibiotic treatment(within the first 7 days post operative)
  • cost for the IDA/IDE treatment and blood product costs(within the first 7 days after surgery)
  • major adverse cardiac and cerebrovascular events(within the first 7 days after surgery)

Study Sites (1)

Loading locations...

Similar Trials